Biotech Values

[genisi]

Updated for Tysbari 1Q10 sales as reported yesterday by BIIB:

In the first quarter global sales of Tysabri rose 28 percent to $292 million.
As of the end of March, about 50,300 patients were on commercial and clinical Tysabri therapy worldwide. That compares with a figure of 48,800 patients as of the end of 2009.

http://uk.finance.yahoo.com/news/update-2-biogen-profit-falls-on-charges-tysabri-sales-rise-targetukfocus-e2ed5943dbeb.html